{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T12:06:09Z","timestamp":1793361969774,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Euglycemic diabetic ketoacidosis associated with SGLT2 inhibitors is a rare, relatively new and potentially fatal clinical entity, characterized by metabolic acidosis with normal or only moderately elevated glycemia. The mechanisms are not fully understood but involve increased ketogenesis and complex renal metabolic dysfunction, resulting in both ketoacidosis and hyperchloremic acidosis. We report a rare case of fatal empagliflozin-associated acidosis with profound hyperchloremia and review its pathogenesis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A patient with type 2 diabetes mellitus treated with empagliflozin underwent an elective hip replacement surgery. Since day 4 after surgery, he felt generally unwell, leading to cardiac arrest on the day 5. Empagliflozin-associated euglycemic diabetic ketoacidosis with severe hyperchloremic acidosis was identified as the cause of the cardiac arrest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This unique case documents the possibility of severe SGLT2 inhibitor-associated mixed metabolic acidosis with a predominant hyperchloremic component. Awareness of this possibility and a high index of suspicion are crucial for correct and early diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12902-023-01339-w","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T06:02:31Z","timestamp":1681452151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis"],"prefix":"10.1186","volume":"23","author":[{"given":"Michal","family":"Sitina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Lukes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Sramek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"1339_CR1","doi-asserted-by":"crossref","unstructured":"Braunwald E. Gliflozins in the management of Cardiovascular Disease. N Engl J Med. 2022 May;26(21):2024\u201334.","DOI":"10.1056\/NEJMra2115011"},{"key":"1339_CR2","doi-asserted-by":"crossref","unstructured":"Vaduganathan M, Docherty KF, Claggett BL, Jhund PS, de Boer RA, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022 Sep;400(3):757\u201367.","DOI":"10.1016\/S0140-6736(22)01429-5"},{"key":"1339_CR3","doi-asserted-by":"crossref","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, et al. CREDENCE trial investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019 Jun;13(24):2295\u2013306.","DOI":"10.1056\/NEJMoa1811744"},{"key":"1339_CR4","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, et al. DAPA-CKD trial committees and investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020 Oct;8(15):1436\u201346."},{"key":"1339_CR5","doi-asserted-by":"crossref","unstructured":"Belkin MN, Cifu AS, Pinney S. Management of Heart Failure. JAMA. 2022 Oct4;328(13):1346\u20131347.","DOI":"10.1001\/jama.2022.16667"},{"key":"1339_CR6","doi-asserted-by":"crossref","unstructured":"de Boer IH, Caramori ML, Chan JCN, Heerspink HJL, Hurst C et al. Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. Kidney Int. 2020Oct;98(4):839\u2013848.","DOI":"10.1016\/j.kint.2020.06.024"},{"key":"1339_CR7","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, ESC Scientific Document Group, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep;21(36):3599\u2013726."},{"key":"1339_CR8","unstructured":"FDA approves label changes. to SGLT2 inhibitors regarding temporary discontinuation of medication before scheduled surgery. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious. Accessed March 23, 2020"},{"key":"1339_CR9","doi-asserted-by":"crossref","unstructured":"Koufakis T, Mustafa OG, Ajjan RA, Garcia-Moll X, Zebekakis P, et al. From Skepticism to Hope: the Evolving Concept of the initiation and use of sodium-glucose cotransporter 2 inhibitors in hospitalized patients. Drugs. 2022 Jun;82(9):949\u201355.","DOI":"10.1007\/s40265-022-01730-2"},{"key":"1339_CR10","doi-asserted-by":"crossref","unstructured":"Kosiborod MN, Esterline R, Furtado RHM, Oscarsson J, Gasparyan SB, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021 Sep;9(9):586\u201394.","DOI":"10.1016\/S2213-8587(21)00180-7"},{"key":"1339_CR11","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00125-017-4301-8","volume":"60","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA adverse event reporting system. Diabetologia. 2017;60:1385\u20139.","journal-title":"Diabetologia"},{"key":"1339_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12902-021-00922-3","volume":"22","author":"A Charoenpiriya","year":"2022","unstructured":"Charoenpiriya A, Chailurkit L, Ongphiphadhanakul B. Comparisons of biochemical parameters and diabetic ketoacidosis severity in adult patients with type 1 and type 2 diabetes. BMC Endocr Disord. 2022;22:7.","journal-title":"BMC Endocr Disord"},{"key":"1339_CR13","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2337\/diab.30.4.310","volume":"30","author":"MS Oh","year":"1981","unstructured":"Oh MS, Banerji MA, Carroll HJ. The mechanism of hyperchloremic acidosis during the recovery phase of diabetic ketoacidosis. Diabetes. 1981;30:310\u20133.","journal-title":"Diabetes"},{"key":"1339_CR14","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1186\/cc3789","volume":"9","author":"JA Kellum","year":"2005","unstructured":"Kellum JA. Clinical review: reunification of acid-base physiology. Crit Care. 2005;9:500\u20137.","journal-title":"Crit Care"},{"key":"1339_CR15","doi-asserted-by":"publisher","first-page":"14379","DOI":"10.1074\/jbc.REV120.008387","volume":"295","author":"RJ Perry","year":"2020","unstructured":"Perry RJ, Shulman GI. Sodium-glucose cotransporter-2 inhibitors: understanding the mechanisms for therapeutic promise and persisting risks. J Biol Chem. 2020;295:14379\u201390.","journal-title":"J Biol Chem"},{"key":"1339_CR16","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.2215\/CJN.17621120","volume":"16","author":"BF Palmer","year":"2021","unstructured":"Palmer BF, Clegg DJ. Euglycemic ketoacidosis as a complication of SGLT2 inhibitor therapy. Clin J Am Soc Nephrol. 2021;16:1284\u201391.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1339_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1159\/000517305","volume":"52","author":"BF Palmer","year":"2021","unstructured":"Palmer BF, Clegg DJ. Starvation ketosis and the kidney. Am J Nephrol. 2021;52:467\u201378.","journal-title":"Am J Nephrol"},{"key":"1339_CR18","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/s41467-019-08466-w","volume":"10","author":"RJ Perry","year":"2019","unstructured":"Perry RJ, Rabin-Court A, Song JD, Cardone RL, Wang Y, Kibbey RG, Shulman GI. Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats. Nat Commun. 2019;10:548.","journal-title":"Nat Commun"},{"key":"1339_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1002\/phar.1881","volume":"37","author":"KR Burke","year":"2017","unstructured":"Burke KR, Schumacher CA, Harpe SE. SGLT2 inhibitors: a systematic review of Diabetic Ketoacidosis and related risk factors in the primary literature. Pharmacotherapy. 2017;37:187\u201394.","journal-title":"Pharmacotherapy"},{"key":"1339_CR20","doi-asserted-by":"crossref","unstructured":"Blau JE, Tella SH, Taylor SI, Rother KI. Ketoacidosis associated with SGLT2 inhibitor treament: Analysis of FAERS data. Diabetes Metab Res Rev2017;33","DOI":"10.1002\/dmrr.2924"},{"key":"1339_CR21","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1056\/NEJMra1207788","volume":"372","author":"KS Kamel","year":"2015","unstructured":"Kamel KS, Halperin ML. Acid-base problems in diabetic ketoacidosis. N Engl J Med. 2015;372:1969\u201370.","journal-title":"N Engl J Med"},{"key":"1339_CR22","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12882-020-01930-6","volume":"21","author":"E Sampani","year":"2020","unstructured":"Sampani E, Sarafidis P, Dimitriadis C, Kasimatis E, Daikidou D, Bantis K, Papanikolaou A, Papagianni A. Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review. BMC Nephrol. 2020;21:276.","journal-title":"BMC Nephrol"},{"key":"1339_CR23","doi-asserted-by":"publisher","first-page":"F712","DOI":"10.1152\/ajprenal.00264.2020","volume":"319","author":"A Onishi","year":"2020","unstructured":"Onishi A, Fu Y, Patel R, Darshi M, Crespo-Masip M, Huang W, Song P, Freeman B, Kim YC, Soleimani M, Sharma K, Thomson SC, Vallon V. A role for tubular Na+\/H + exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin. Am J Physiol Renal Physiol. 2020;319:F712\u201328.","journal-title":"Am J Physiol Renal Physiol"},{"key":"1339_CR24","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1152\/ajplegacy.1976.231.3.880","volume":"231","author":"P Vinay","year":"1976","unstructured":"Vinay P, Lemieux G, Cartier P, Ahmad M. Effect of fatty acids on renal ammoniagenesis in in vivo and in vitro studies. Am J Physiol. 1976;231:880\u20137.","journal-title":"Am J Physiol"},{"key":"1339_CR25","unstructured":"Hall JE, Hall ME, Guyton AC. Guyton and Hall textbook of medical physiology. Elsevier; 2021."},{"key":"1339_CR26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/ki.1980.7","volume":"17","author":"L Goldstein","year":"1980","unstructured":"Goldstein L, Boylan JM, Schr\u00f6ck H. Adaptation of renal ammonia production in the diabetic ketoacidotic rat. Kidney Int. 1980;17:57\u201365.","journal-title":"Kidney Int"},{"key":"1339_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.0954-6820.1952.tb15684.x","volume":"144","author":"A Warming-Larsen","year":"1952","unstructured":"Warming-Larsen A. Renal excretion of ketone bodies. II Acta Med Scand. 1952;144:197\u2013200.","journal-title":"II Acta Med Scand"},{"key":"1339_CR28","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.psyneuen.2014.03.008","volume":"45","author":"B Kubera","year":"2014","unstructured":"Kubera B, Hubold C, Wischnath H, Zug S, Peters A. Rise of ketone bodies with psychosocial stress in normal weight men. Psychoneuroendocrinology. 2014;45:43\u20138.","journal-title":"Psychoneuroendocrinology"},{"key":"1339_CR29","doi-asserted-by":"crossref","unstructured":"Arlas N, Vandiver JW. Fanconi syndrome and euglycemic diabetic ketoacidosis secondary to canagliflozin use in a type 2 diabetic. Journal of Clinical and Translational Endocrinology 2022: Case Reports, Volume\u00a023.","DOI":"10.1016\/j.jecr.2022.100109"},{"key":"1339_CR30","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/nep.13094","volume":"23","author":"DH Esprit","year":"2018","unstructured":"Esprit DH, Koratala A. Fanconi syndrome associated with SGLT2 inhibitor, canagliflozin. Nephrol (Carlton). 2018;23:493.","journal-title":"Nephrol (Carlton)"},{"key":"1339_CR31","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1093\/ajhp\/zxz226","volume":"76","author":"N Khan","year":"2019","unstructured":"Khan N, Tso K, Broussard J, Dziuba M. Canagliflozin-induced Fanconi syndrome in a patient with previously unrecognized type 1 diabetes. Am J Health Sys Pharm. 2019;76:1930\u20133.","journal-title":"Am J Health Sys Pharm"},{"key":"1339_CR32","doi-asserted-by":"crossref","unstructured":"Koufakis T, Mustafa OG, Ajjan RA, Garcia-Moll X, Zebekakis P, et al. The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: is the risk worth taking? J Clin Pharm Ther. 2020 Oct;45(5):883\u201391.","DOI":"10.1111\/jcpt.13107"},{"key":"1339_CR33","doi-asserted-by":"crossref","unstructured":"Khunti K, Aroda VR, Bhatt DL, Bozkurt B, Buse JB, et al. Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: a perspective based on the updated evidence. Diabetes Obes Metab. 2022 Nov;24(11):2071\u201380.","DOI":"10.1111\/dom.14805"}],"updated-by":[{"DOI":"10.1186\/s12902-023-01436-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T00:00:00Z","timestamp":1693180800000}}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01339-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-023-01339-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01339-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T12:10:37Z","timestamp":1700395837000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-023-01339-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1339"],"URL":"https:\/\/doi.org\/10.1186\/s12902-023-01339-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2308651\/v1","asserted-by":"object"}]},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]},"assertion":[{"value":"24 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12902-023-01436-w","URL":"https:\/\/doi.org\/10.1186\/s12902-023-01436-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ethics approval and consent to participate are not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare to have the written informed consent of the wife of the patient involved in the reported case to prepare and publish the case report. The patient himself could not give his consent for obvious reasons.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}